Amounts in the record
Thymosin Alpha-1 dosage: the clinical trial record
The recurring amount looks familiar. The patients, accompanying care and timing differ substantially.
Thymosin alpha 1 dosage across studies
The amount 1.6 mg turns up repeatedly in Thymosin Alpha-1 studies. Seeing it recur can create a false sense that the papers have settled on one protocol. The actual records describe chronic hepatitis treatment, intensive-care sepsis trials and severe COVID-19 cohorts, with different clinical circumstances and outcomes.
The table records treatment administered by study teams; it cannot determine an individual's dose or a safe course of treatment.
| Population or named study | What participants received |
|---|---|
| Chronic hepatitis B or C studies | 1.6 mg by subcutaneous injection, twice weekly, alongside the study's other care. |
| ETASS: severe sepsis | 1.6 mg subcutaneously every 12 hours for 5 days, then once daily for 2 days. |
| TESTS: adults with sepsis | 1.6 mg subcutaneously every 12 hours for 7 days. |
| Severe COVID-19 retrospective cohort | 1.6 mg subcutaneously daily. |
Subcutaneous means under the skin. The table describes a route used in clinical research, without providing preparation or injection instructions.
Ranges in the clinical review
The review by Dominari and colleagues reports single subcutaneous doses ranging from 0.8 to 6.4 mg and multiple-dose regimens of 1.6–16 mg over five to seven days. The same review describes 1.6 mg twice weekly as a common chronic hepatitis regimen.
I regard those ranges as the boundaries of a literature summary, rather than a menu. A range gathers different studies together; it leaves the clinical judgement inside each study. The outcome record matters as much as the amount: TESTS found no significant mortality benefit with its studied regimen.
The recurring dose did not produce a recurring result. TESTS found no statistically significant survival benefit in sepsis.
Thymosin alpha 1 injection and half-life
The pharmacology summarised in the clinical review describes a blood concentration peak one to two hours after subcutaneous injection in healthy volunteers, an elimination half-life of approximately two hours, and levels approaching baseline within about 24 hours. Half-life describes the time for the blood concentration to fall by half.
The duration of an immune effect requires its own evidence. A concentration curve cannot establish when someone will feel better, how long any benefit lasts or which time of day produces a better outcome. The studies cited here do not compare morning with night.
Research preparations also raise questions of identity, purity and sterile handling. There are no mixing directions on this page. A licensed U.S. clinician may assess a request for compounded thymosin alpha-1 and may decline it; compounded medication has no FDA approval.